Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 6,279 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $75.04, for a total value of $471,176.16. Following the completion of the transaction, the insider now owns 19,436 shares of the company’s stock, valued at approximately $1,458,477.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Darin Lippoldt also recently made the following trade(s):

  • On Wednesday, November 15th, Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $73.05, for a total value of $723,195.00.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down $1.00 during midday trading on Wednesday, hitting $70.98. The company’s stock had a trading volume of 603,900 shares, compared to its average volume of 1,106,568. Neurocrine Biosciences, Inc. has a twelve month low of $37.35 and a twelve month high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the previous year, the business posted ($0.43) EPS. analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Teachers Advisors LLC grew its position in shares of Neurocrine Biosciences by 5.6% during the 1st quarter. Teachers Advisors LLC now owns 82,647 shares of the company’s stock valued at $3,579,000 after acquiring an additional 4,360 shares during the period. Aperio Group LLC grew its position in shares of Neurocrine Biosciences by 3.7% during the 2nd quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock valued at $1,027,000 after acquiring an additional 789 shares during the period. Sei Investments Co. grew its position in shares of Neurocrine Biosciences by 34.6% during the 2nd quarter. Sei Investments Co. now owns 106,389 shares of the company’s stock valued at $4,894,000 after acquiring an additional 27,330 shares during the period. TD Asset Management Inc. grew its position in shares of Neurocrine Biosciences by 79.0% during the 2nd quarter. TD Asset Management Inc. now owns 156,600 shares of the company’s stock valued at $7,204,000 after acquiring an additional 69,100 shares during the period. Finally, Pictet Asset Management Ltd. grew its position in shares of Neurocrine Biosciences by 12.3% during the 2nd quarter. Pictet Asset Management Ltd. now owns 1,140,859 shares of the company’s stock valued at $49,593,000 after acquiring an additional 124,965 shares during the period.

A number of equities analysts recently issued reports on NBIX shares. Jefferies Group restated a “buy” rating and issued a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Citigroup restated a “buy” rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Piper Jaffray Companies restated a “buy” rating and issued a $76.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $58.00 target price on shares of Neurocrine Biosciences in a research note on Sunday, September 17th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $78.88.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 6,279 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/06/insider-selling-neurocrine-biosciences-inc-nbix-insider-sells-6279-shares-of-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.